Borrow Ray, Andrews Nick, Findlow Helen, Waight Pauline, Southern Joanna, Crowley-Luke Annette, Stapley Lorraine, England Anna, Findlow Jamie, Miller Elizabeth
Vaccine Evaluation Unit, Health Protection Agency, Manchester Medical Microbiology Partnership, P.O. Box 209, Clinical Sciences Building 2, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom.
Clin Vaccine Immunol. 2010 Jan;17(1):154-9. doi: 10.1128/CVI.00384-09. Epub 2009 Nov 11.
The kinetics of antibody persistence following the administration of a combination meningococcal serogroup C and Haemophilus influenzae type b (Hib) conjugate vaccine (Menitorix) in the second year of life in children primed with two doses of one of three monovalent meningococcal serogroup C (MCC) vaccines was investigated. The study subjects were administered either Menitorix at 12 to 15 months of age, followed by the seven-valent pneumococcal conjugate vaccine (PCV7) and the measles, mumps, and rubella vaccine 4 to 6 weeks later, or all three vaccines concomitantly at 12 to 15 months of age. Blood samples were collected before and 1, 2, 12, and 24 months after the boosting. Sera were analyzed for meningococcal serogroup C serum bactericidal antibody (SBA) and IgG as well as Hib-polyribosylribitol phosphate (PRP)-specific IgG. The antibody persistence data from this study were compared to those of a prior study of Southern et al. (Clin. Vaccine Immunol. 14:1328-1333, 2007) in which children were given three primary doses of a vaccine containing both the MCC and the Hib vaccines but were boosted only with a Hib conjugate vaccine. The magnitude of the meningococcal SBA geometric mean titer was higher for those subjects primed with the MCC vaccine conjugated to tetanus toxoid (NeisVac-C) than for those primed with one of two MCC vaccines conjugated to CRM(197) (Menjugate or Meningitec) up to 1 year following boosting. Two years after boosting, the percentages of subjects with putatively protective SBA titers of > or =8 for children primed with NeisVac-C, Menjugate, and Meningitec were 43%, 22%, and 23%, respectively. Additional booster doses of the MCC vaccine may be required in the future to maintain good antibody levels; however, there is no immediate need for a booster during adolescence, as mathematical modeling has shown that persisting herd immunity is likely to control disease for a number of years.
对在生命第二年接种过两剂三种单价C群脑膜炎球菌（MCC）疫苗之一进行基础免疫的儿童，给予C群脑膜炎球菌和b型流感嗜血杆菌（Hib）联合疫苗（Menitorix）后抗体持久性的动力学进行了研究。研究对象在12至15月龄时接种Menitorix，4至6周后接种七价肺炎球菌结合疫苗（PCV7）和麻疹、腮腺炎、风疹疫苗，或者在12至15月龄时同时接种这三种疫苗。在加强免疫前以及加强免疫后1、2、12和24个月采集血样。分析血清中的C群脑膜炎球菌血清杀菌抗体（SBA）、IgG以及Hib - 多聚核糖核糖醇磷酸（PRP）特异性IgG。将本研究的抗体持久性数据与Southern等人先前的一项研究（《临床疫苗免疫学》14:1328 - 1333，2007年）的数据进行比较，在先前的研究中，儿童接种了含MCC和Hib疫苗的三剂基础疫苗，但仅用Hib结合疫苗进行加强免疫。在加强免疫后长达1年的时间里，用与破伤风类毒素结合的MCC疫苗（NeisVac - C）进行基础免疫的受试者，其脑膜炎球菌SBA几何平均滴度高于用与CRM(197)结合的两种MCC疫苗之一（Menjugate或Meningitec）进行基础免疫的受试者。在加强免疫两年后，用NeisVac - C、Menjugate和Meningitec进行基础免疫的儿童中，推定保护性SBA滴度≥8的受试者百分比分别为43%、22%和23%。未来可能需要额外接种MCC疫苗加强剂以维持良好的抗体水平；然而，青春期目前没有立即进行加强免疫的必要，因为数学模型显示，持续的群体免疫可能在数年时间内控制疾病。
